摘要
目的探讨血管内支架治疗合并其他头颈动脉狭窄（other craniocervical artery stenoses，OCAS）的粥样硬化性锁骨下动脉狭窄闭塞性病变（subclavian arterystenosis-occlusion，SASO）患者的疗效。方法回顾性分析接受血管内支架治疗的粥样硬化性SASO患者的临床资料，包括人口统计学特征、血管危险因素、合并OCAS情况以及SASO支架治疗和随访结果。结果共纳入65例SASO患者，其中男性47例，女性18例，平均年龄（64±9）岁，46例（70．8％）合并OCAS。总的技术成功率为95．4％，其中狭窄患者58例（98．1％），完全闭塞患者7例（71．4％）。共有4例发生并发症，无介入相关的严重卒中和死亡。平均随访（24±19）个月，发现再狭窄6例和临床相关事件10例，主要发生于合并OCAS的患者。术后12、24个月和随访结束时首次血管成形通畅率分别为94．5％、81．8％和81．8％，无临床相关事件存活率分别为92．9％、74．6％和68．3％。结论血管内支架可安全和有效地治疗合并OCAS的SASO患者，其总体临床转归在一定程度上受OCAS的影响。
Objective To investigate the efficacy of endovascular stenting complicating other eraniocervical artery stenosis （OCAS） in patients with atherosclerotic subclavian artery stenosis/occlusion （SASO）. Methods The clinical data of receiving endovascular stenting therapy in patients with atherosclerotic SASO were analyzed retrospectively, including demographic characteristics, vascular risk factors, complicating OCAS, as well as stenting for SASO and follow-up results. Results A total of 65 patients with SASO were included in the study, 47 of them were males and 18 were females （mean age of 64 ＋9 years）. Forty-six patients （70. 8%） complicated OCAS. The overall technical success rate was 95.4%, in which the patients with stenosis （n=58） were 98. 1% and those with complete occlusion （n=7） were 71.4%. The complications occurred in 4 patients. There were no intervention-related serious stroke anddeath. Mean follow-up was 24±19 months, 6 patients with restenosis and 10 with clinically relevant events were found. They mainly occurred in patients with OCAS. The first angioplasty patency rates were 94. 5%, 81.8% and 81.8%, respectively at 12 and 24 months after procedure and at the end of follow-up. The survival rates of no clinically relevant events were 92. 9%, 74. 6% and 68.3%, respectively. Conelusiom Endovascular stenting can safely and effectively treat the SASO patients complicating OCAS. Its overall clinical outcome may be affected to some extent by OCAS.
出处
《国际脑血管病杂志》
北大核心
2011年第11期811-817,共7页
International Journal of Cerebrovascular Diseases
